Using Humanin to Diagnose and Predict Kidney Injury After Heart Transplant
Humanin's Value for Early Diagnosis and Short-term Prognosis in Patients With AKI After Heart Transplantation
This study is testing if a new marker called Humanin can help doctors spot and predict kidney problems early in adults who have just had a heart transplant.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 60 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Guangdong Provincial People's Hospital Academic / other |
| Locations | 1 site (Guangdong, Guangzhou) |
| Trial ID | NCT06125249 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate the effectiveness of Humanin as a novel biomarker for the early diagnosis and short-term prognosis of acute kidney injury (AKI) in patients following heart transplantation. Researchers will compare Humanin levels in patients who develop AKI with those who do not, to determine its predictive value. Given the high incidence of AKI post-heart transplant and its potential complications, identifying a reliable biomarker could significantly improve patient management. The study will involve adult patients with normal renal function prior to surgery at Guangdong Provincial People's Hospital.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older undergoing heart transplantation with normal baseline renal function.
Not a fit: Patients under 18 years of age or those with incomplete baseline medical records will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to earlier and more accurate diagnosis of AKI, potentially improving patient outcomes after heart transplantation.
How similar studies have performed: While the use of Humanin as a biomarker is relatively novel, previous studies have shown promise in other conditions, suggesting potential for success in this context.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Guangdong Provincial People's Hospital performs heart transplantation；Adult patients ≥ 18 years of age, male or female；Basic renal function is normal before surgery；The patient's baseline medical records are complete, including basic heart diseases, comorbidities, hemoglobin, renal function, urine protein quantification, serum albumin, lactic acid, C-reactive protein, heart transplantation operation time, preoperative and postoperative medication and blood pressure, blood transfusion history, ICU length of stay, cardiac ultrasound (including LVEF), etc； Exclusion Criteria: Age\< 18 years；Baseline data were missing
Where this trial is running
Guangdong, Guangzhou
- Guangdong Provincial People's Hospital — Guangdong, Guangzhou, China (Recruiting)
Study contacts
- Principal investigator: zhilian PP li, doctor — Guangdong Provincial People's Hospital
- Study coordinator: zhilian li, doctor
- Email: lizhilian@gdph.org.cn
- Phone: 13580560903
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.